Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells bv IκB kinase α

被引:63
作者
Dan, Han C. [1 ]
Adli, Mazhar [1 ]
Baldwin, Albert S. [1 ]
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biol, Sch Med, Chapel Hill, NC 27599 USA
关键词
D O I
10.1158/0008-5472.CAN-07-1232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mammalian target of rapamycin (mTOR) is a mediator of cell growth, survival, and energy metabolism at least partly through its ability to regulate mRNA translation. mTOR is activated downstream of growth factors, insulin, and Akt-dependent signaling associated with oncoprotein expression or loss of the tumor-suppressor PTEN. In this regard, mTOR activity is associated with cancer cell growth and survival. Here, we have explored an involvement of the I kappa B kinase (IKK) pathway, associated with nuclear factor-kappa B activation, in controlling mTOR activity. The experiments show that IKK alpha controls mTOR kinase activity in Akt-active, PTEN-null prostate cancer cells, with less involvement by IKK beta. In these cells, IKK alpha associates with mTOR, as part of the TORC1 complex, in an Akt-dependent manner. Additionally, IKK alpha is required for efficient induction of mTOR activity downstream of constitutively active Akt expression. The results indicate a novel role for IKK alpha in controlling mTOR function in cancer cells with constitutive Akt activity.
引用
收藏
页码:6263 / 6269
页数:7
相关论文
共 26 条
[11]   Signaling to NF-κB [J].
Hayden, MS ;
Ghosh, S .
GENES & DEVELOPMENT, 2004, 18 (18) :2195-2224
[12]   TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling [J].
Inoki, K ;
Li, Y ;
Zhu, TQ ;
Wu, J ;
Guan, KL .
NATURE CELL BIOLOGY, 2002, 4 (09) :648-657
[13]   NFκB:: Linking inflammation and immunity to cancer development and progression [J].
Karin, M ;
Greten, FR .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (10) :749-759
[14]   GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR [J].
Kim, DH ;
Sarbassov, DD ;
Ali, SM ;
Latek, RR ;
Guntur, KVP ;
Erdjument-Bromage, H ;
Tempst, P ;
Sabatini, DM .
MOLECULAR CELL, 2003, 11 (04) :895-904
[15]   MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery [J].
Kim, DH ;
Sarbassov, DD ;
Ali, SM ;
King, JE ;
Latek, RR ;
Erdjument-Bromage, H ;
Tempst, P ;
Sabatini, DM .
CELL, 2002, 110 (02) :163-175
[16]   NF-κB and IKK as therapeutic targets in cancer [J].
Kim, HJ ;
Hawke, N ;
Baldwin, AS .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (05) :738-747
[17]   Inflammation-associated cancer:: NF-κB is the lynchpin [J].
Li, QT ;
Withoff, S ;
Verma, IM .
TRENDS IN IMMUNOLOGY, 2005, 26 (06) :318-325
[18]   TSC2: filling the GAP in the mTOR signaling pathway [J].
Li, Y ;
Corradetti, MN ;
Inoki, K ;
Guan, KL .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (01) :32-38
[19]   Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38 [J].
Madrid, LV ;
Mayo, MW ;
Reuther, JY ;
Baldwin, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (22) :18934-18940
[20]   Akt-regulated pathways in prostate cancer [J].
Majumder, PK ;
Sellers, WR .
ONCOGENE, 2005, 24 (50) :7465-7474